Evidence-based pharmacological management of chronic neuropathic pain
Keywords:
Neuropathic pain, Neuralgia, Pharmacological management, Algorithm, Analgesic agents, Evidence-based, Diabetic peripheral neuropathyAbstract
Neuropathic pain (NP) is a chronic, debilitating symptomatology of lesions/injuries of the central and peripheral nervous system. As per pooled estimates, the prevalence is 7-8% in the general population; however, the prevalence varies with different neuropathic conditions. The aetiology can range from peripheral neuropathic conditions viz. peripheral diabetic neuropathic pain (PDNP), post-herpetic neuralgia (PHN), trigeminal neuralgia, HIV- associated polyneuropathy, cervical radiculopathy to central neuropathic conditions, viz. central post-stroke pain, spinal cord injury and the neuropathic pain associated with multiple sclerosis. Apart from the symptomatic perception of pain, neuropathic pain affects the cognitive and emotional aspects of the affected individual. The pain, being debilitating and resistant to over-the-counter analgesics, diminishes the quality of life, disrupts sleep and leads to psychiatric complications such as comorbid anxiety and depression. The management is palliative and involves drugs, psychological intervention, stimulations and nerve-blocking techniques. This review concentrates on the pharmacological therapeutic options available and focuses on the selection of the agent/s in accordance with the evidence. The first-line treatment includes the tricyclic antidepressants ([TCAs]; amitriptyline, nortriptyline), selective serotonin norepinephrine inhibitors ([SNRIs]; duloxetine, venlafaxine), calcium channel alpha 2 - delta ligands (pregabalin, gabapentin), carbamazepine and oxcarbazepine. Lidocaine plasters are first-line options for specific focal conditions such as post-herpetic neuralgia. The second-line therapy includes the opioid analgesics and tramadol. The choice of drug selection should complement the patient’s age, type of neuropathic condition, tolerability to an agent, comorbid condition and cost-effectiveness. Management must be individualized with a realistic and composite goal of making the pain tolerable and improving the cognitive and emotional well-being.
References
Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008;137:681-8.
Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9.
Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7.
Schmader KE. Epidemiology and impact on the quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.
Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377-84.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-4.
Gonzalez-Duarte A. Robinson-Papp J, Simpson DM. Diagnosis and management of HIV-associated neuropathy. Neurol Clin 2008;26:821-32.
Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A Review of the Epidemiology of Painful Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, and Less Commonly Studied Neuropathic Pain Conditions. Pain Pract 2008;8:45-56.
Galluzzi KE. Managing Neuropathic Pain. J Am Osteopath Assoc 2007;107:ES39-48.
Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-51.
Finnerup NB, Sindrup SH, Jensen TS. The evidence of pharmacological treatment of neuropathic pain. Pain 2010;150:573-81.
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, et al. Pharmacological management of chronic neuropathic pain – Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007;12:13-21.
Attal N, Cruccua G, Barona R, Haanpaa M, Hanssona P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 Revision. Eur J Neurol 2010;17:1113-e88.
Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, et al. Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. Mayo Clin Proc 2010;85:S3-S14.
Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Neurology 2011;76:1758-65.
Ian Gliron, C. Peter N. Watson, Catherine M. Cahill, Dwight E. Mouline. Neuropathic pain; a practical guide for the clinician. CMAJ 2006;175:265-75.
Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, et al. Consensus Guidelines: Treatment Planning and Options. Mayo Clin Proc 2006;81(4 Suppl):S12-25.
Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;7:CD008943.
Ian Gilron, Joan M. Bailey, R.N., DongshengTu, Ronald R. Holden,Donald F. Weaver, Robyn L. Houlden. Morphine, Gabapentin, or Their Combination for Neuropathic Pain. N Engl J Med 2005;352:1324-34.
Guastella V, Mick G, Laurent B. Non pharmacologic treatment of neuropathic pain. Presse Med 2008;37(2 Pt 2):354-7.
Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. American Academy of Neurology Society; European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 2008;15:1013-28.
Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21.
Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-80.
Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70:2305-13.
Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, et al. Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003;60:1508-14.
Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury, a placebo-controlled trial. Neurology 2006;67:1792-800.
Taylor JC, Brauer S, Espir ML. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981;57:16-8.
Gomez-Arguelles JM, Dorado R, Sepulveda JM, Herrera A, et al. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. J Clin Neurosci 2008;15:516-9.
Vorobeychik Y, Gordin V, Mao J, Chen L. Combination Therapy for Neuropathic Pain. A Review of Current Evidence. CNS Drugs 2011;25:1023-34.
Zin CS, Nissen LM, O’Callaghan JP, et al. A randomized controlled trial of oxycodone versus placebo in patients with post-herpetic neuralgia and painful diabetic neuropathy with pregabalin. J Pain 2010;11:462-71.
